Standard BioTools (NASDAQ:LAB) Stock Price Up 5.8%

Standard BioTools Inc. (NASDAQ:LAB - Get Free Report) shares shot up 5.8% during mid-day trading on Monday . The company traded as high as $2.91 and last traded at $2.90. 560,592 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 2,039,156 shares. The stock had previously closed at $2.74.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group began coverage on Standard BioTools in a report on Thursday. They issued a "buy" rating and a $3.25 price objective for the company.

Standard BioTools Trading Up 5.1 %

The business has a fifty day moving average price of $2.54 and a 200-day moving average price of $2.32. The stock has a market capitalization of $835.55 million, a PE ratio of -3.03 and a beta of 1.64.

Standard BioTools (NASDAQ:LAB - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.05. The firm had revenue of $28.19 million during the quarter, compared to analysts' expectations of $28.00 million. On average, equities analysts anticipate that Standard BioTools Inc. will post -0.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Casdin Partners Master Fund, L bought 250,000 shares of the firm's stock in a transaction dated Monday, March 4th. The stock was purchased at an average price of $2.57 per share, with a total value of $642,500.00. Following the transaction, the director now owns 11,496,525 shares of the company's stock, valued at $29,546,069.25. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 53.10% of the company's stock.

Institutional Trading of Standard BioTools

A number of institutional investors and hedge funds have recently modified their holdings of the business. SMH Capital Advisors Inc. purchased a new position in shares of Standard BioTools in the 4th quarter worth $26,000. Jane Street Group LLC purchased a new position in shares of Standard BioTools in the 3rd quarter worth $28,000. Marshall Wace LLP purchased a new position in shares of Standard BioTools in the 2nd quarter worth $31,000. Walleye Capital LLC purchased a new position in shares of Standard BioTools in the 2nd quarter worth $40,000. Finally, Acadian Asset Management LLC purchased a new position in shares of Standard BioTools in the 3rd quarter worth $50,000. Institutional investors own 53.74% of the company's stock.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.